Endogenous Energy Production in Critically Ill Patients (eEPIC)

Karolinska University Hospital

Status: Not yet enrolling

Conditions: Metabolism and Nutrition Disorder; Critical Illness

Treatments: Other: Stable isotope tracers; Dietary Supplement: Parenteral nutrition

Study type: Interventional

Funder types: Other

Identifiers

NCT07059988

2024-9306

Details and patient eligibility

About

The aim of this study is to investigate when critically ill patients transition from a non-suppressible catabolism to a normal response to feeding.

Endogenous production of glucose, fat and protein will be studied on a minimum of two occasions in mechanically ventilated ICU patients, in a fasted state and during parenteral nutrition. Substrate kinetics are estimated by a tracer dilution method using infusions of isotopically labeled glucose, glycerol and phenylalanine. Blood sampling for metabolomics analysis will be performed to elucidate potential biomarkers indicating an anabolic response to nutrition.

Full description

Background and aims

Critical illness is characterized by several metabolic alterations, including an upregulation of catabolic pathways promoting endogenous energy substrate production. In contrast to starvation catabolism, this endogenous energy supply cannot be suppressed by feeding in the early acute phase of critical illness. This observation is one of the reasons that current guidelines recommend hypocaloric nutrition during the first week in ICU [1]. However, it is not known when this anabolic resistance subsides and a transition towards a normal response to feeding occurs.

The aims of this study are two-fold: 1) to investigate the temporal changes in non-suppressible endogenous energy production during critical illness, and 2) identify potential biomarkers indicating a normalized response to exogenous nutrients.

Protocol

For ICU patients, the protocol is first performed within 24-72 hours (early acute phase) from ICU admission. The protocol will be repeated if an enrolled patient is still in the ICU 120-168 hours (late acute phase) and 240-288 hours (late phase) after the first study session.

Infusions of intravenous (i.v.) glucose, enteral/parenteral nutrition (EN/PN) and insulin are stopped at 02:00 hours. Blood glucose concentrations will be monitored at least hourly during the fasting period. The protocol will be terminated in case of hypoglycaemia (<4 mmol/L), and the patient will be excluded from the trial. The infusion rate of propofol will remain unchanged from 04:00 unless a change is clinically indicated, determined by the nurse or physician. Healthy controls will be asked to fast from midnight. In the control group, a peripheral i.v. line and a radial arterial line will be placed under local anaesthesia.

Baseline blood samples will be drawn from the arterial catheter, whereafter primed i.v. infusions of ring-2H5-phenylalanine, 2H2-glucose, and 2H5-glycerol will be started at 07:00. Measured resting energy expenditure (mREE) is then determined by 20-minute indirect calorimetry (IC) using the Q-NRG device (Cosmed, Rome, Italy) in ventilator or canopy mode. After 165 minutes, four blood samples will be drawn at 5-minute intervals from the arterial catheter to determine glucose, glycerol, and amino acid kinetics in a fasted state. Additional blood samples are drawn to analyze circulating hormones, cytokines, metabolites, and markers of autophagy.

PN (Olimel perifer N4E, Baxter) is then started at a rate that, including calories from propofol and other non-nutritional energy sources, corresponds to 100% of mREE. Repeated blood samples (same as above) are drawn at 45-60, 105-120 and 165-180 minutes after the start of PN. An additional IC is performed during the final 30 minutes of the PN. If hyperglycemia occurs during the PN administration, an insulin infusion will be started to keep blood glucose levels <14 mmol/L.

After the final blood samples, all tracer infusions and PN are stopped. In ICU patients, nutritional therapy will be restarted as prescribed by the care team. In healthy controls, all catheters are removed.

Patients

Adult patients with an estimated ICU length of stay (LOS) >72 hours will be recruited from the intensive care unit (ICU) at Karolinska University Hospital Huddinge, a tertiary university hospital with approximately 800 annual ICU admissions. Exclusion criteria include liver disease (liver transplant, acute or acute-on-chronic liver failure, cirrhosis), diabetes, pancreatic surgery or pancreatitis, pregnancy, intubation for airway protection only, mitochondrial disease, amino acid metabolism disorder, familial hypertriglyceridemia, severe hypertriglyceridaemia (≥ 10 mmol/L), hypoglycemia within the last 72 h, requiring ongoing large-volume resuscitation and/or blood transfusions, readmission within one week of ICU discharge, BMI ≥35, limitations to best supportive care or ongoing insulin/glucose treatment related to hyperkalemia.

Control group

Healthy, age- and sex-matched controls.

Statistical analysis and sample size considerations

Normal distribution will be assumed a priori. Primary and secondary outcomes will be analyzed using Student's T-test for paired or independent samples or one-way ANOVA as appropriate. The level of statistical significance is p ≤ 0.05. Correction for multiple comparisons will not be applied.

Based on previous data describing endogenous glucose production in a fasted and fed state in critically ill patients, 10 subjects in each group are required to detect a 20% difference in change in glucose rate of appearance with 80% power. No similar studies describing glycerol or amino acid kinetics are available for sample size calculations. Due to missing data, dropouts and inter-/intraparticipant variability, 10 patients with measurements of substrate kinetics in both the early acute and late acute phases are required to answer the primary and secondary outcome measures. To identify potential biomarkers of attenuated catabolism, 30 patients who complete the protocol in both the early acute and late acute phases will be included, i.e. two measurements per patient. Ten volunteers will be recruited to an age-matched control group.

Enrollment: 40 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

For the ICU group:

1. ≥18 years old and admitted to the ICU
2. Invasive mechanical ventilation
3. Arterial and central line in situ
4. Expected to remain in ICU >72 hours

For the control group:

1. ≥18 years old

Exclusion criteria

1. Lack of informed consent by patient/next of kin
2. Liver transplant
3. Acute or acute on chronic liver failure
4. Cirrhosis
5. Known diabetes mellitus
6. Pancreatic surgery
7. Acute or chronic pancreatitis
8. Pregnancy
9. Intubated only for airway protection or neurologic deficit
10. Mitochondrial disease
11. Disorder of amino acid metabolism
12. Familial hypertriglyceridemia
13. Severe acquired hypertriglyceridemia (≥10 mmol/L)
14. Requiring treatment of hypoglycemia in the last 72 hours before inclusion.
15. Requiring ongoing large volume resuscitation of crystalloids or blood products
16. >72 hours in ICU before enrollment
17. Readmission to ICU within 1 week of ICU discharge.
18. Morbidly obese (BMI ≥35)
19. Limitations of treatment to best supportive care
20. Ongoing treatment with insulin/glucose related to hyperkalemia

Trial design

Primary purpose: Diagnostic

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

40 participants in 2 patient groups

ICU Patients

Experimental group

Description:

Mechanically ventilated patients admitted to the study site ICU.

Treatment:

Dietary Supplement: Parenteral nutrition

Other: Stable isotope tracers

Control group

Experimental group

Description:

Non-hospitalized study subjects recruited through public advertising at the study site, age-matched on group level.

Treatment:

Dietary Supplement: Parenteral nutrition

Other: Stable isotope tracers